open access

Vol 56, No 1 (2022)
Invited Review Article
Submitted: 2022-01-03
Accepted: 2022-02-11
Published online: 2022-02-23
Get Citation

Use of cannabidiol in the treatment of epilepsy

Maria Mazurkiewicz-Bełdzińska1, Marta Zawadzka1
DOI: 10.5603/PJNNS.a2022.0020
·
Pubmed: 35211946
·
Neurol Neurochir Pol 2022;56(1):14-20.
Affiliations
  1. Department of Developmental Neurology, Medical University of Gdansk, Poland

open access

Vol 56, No 1 (2022)
INVITED REVIEW ARTICLES — LEADING TOPIC
Submitted: 2022-01-03
Accepted: 2022-02-11
Published online: 2022-02-23

Abstract

Introduction. Cannabis sativa has been cultivated for human use for about 5,000 years, and has likewise been used in the treatment of epilepsy for thousands of years.

State of the art. Cannabidiol (CBD), which was isolated from cannabis sativa in 1940, has an anti-seizure effect and no psychoactive activity. Its effectiveness in reducing various types of seizures has been proven in animal seizure and epilepsy models. Recent randomised, placebo-controlled trials have confirmed its effectiveness in patients with drug-resistant epilepsy.

Clinical implications. The aim of this position paper was to present the specific mechanism of CBD’s anti-seizure action and current indications for CBD’s use in epilepsy. The only cannabis-derived drug that has successfully passed clinical trials and has obtained United States Food and Drug Administration and European Medicines Agency approval for epilepsy is Epidiolex®. This paper presents the outcomes of the completed clinical trials with the use of this drug.

Future directions. CBD may be an effective drug in drug-resistant epilepsy, particularly in Dravet Syndrome, Lennox- Gastaut Syndrome and seizures associated with tuberous sclerosis complex. Additional randomised, placebo-controlled studies with CBD are needed.

Abstract

Introduction. Cannabis sativa has been cultivated for human use for about 5,000 years, and has likewise been used in the treatment of epilepsy for thousands of years.

State of the art. Cannabidiol (CBD), which was isolated from cannabis sativa in 1940, has an anti-seizure effect and no psychoactive activity. Its effectiveness in reducing various types of seizures has been proven in animal seizure and epilepsy models. Recent randomised, placebo-controlled trials have confirmed its effectiveness in patients with drug-resistant epilepsy.

Clinical implications. The aim of this position paper was to present the specific mechanism of CBD’s anti-seizure action and current indications for CBD’s use in epilepsy. The only cannabis-derived drug that has successfully passed clinical trials and has obtained United States Food and Drug Administration and European Medicines Agency approval for epilepsy is Epidiolex®. This paper presents the outcomes of the completed clinical trials with the use of this drug.

Future directions. CBD may be an effective drug in drug-resistant epilepsy, particularly in Dravet Syndrome, Lennox- Gastaut Syndrome and seizures associated with tuberous sclerosis complex. Additional randomised, placebo-controlled studies with CBD are needed.

Get Citation

Keywords

cannabidiol, drug-resistant epilepsy, Lennox-Gastaut Syndrome, Dravet Syndrome, tuberous sclerosis

About this article
Title

Use of cannabidiol in the treatment of epilepsy

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 56, No 1 (2022)

Article type

Invited Review Article

Pages

14-20

Published online

2022-02-23

Page views

2390

Article views/downloads

760

DOI

10.5603/PJNNS.a2022.0020

Pubmed

35211946

Bibliographic record

Neurol Neurochir Pol 2022;56(1):14-20.

Keywords

cannabidiol
drug-resistant epilepsy
Lennox-Gastaut Syndrome
Dravet Syndrome
tuberous sclerosis

Authors

Maria Mazurkiewicz-Bełdzińska
Marta Zawadzka

References (41)
  1. Friedman D, Sirven JI. Historical perspective on the medical use of cannabis for epilepsy: Ancient times to the 1980s. Epilepsy Behav. 2017; 70(Pt B): 298–301.
  2. Russo EB. Cannabis and epilepsy: An ancient treatment returns to the fore. Epilepsy Behav. 2017; 70(Pt B): 292–297.
  3. Fasinu PS, Phillips S, ElSohly MA, et al. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy. 2016; 36(7): 781–796.
  4. Arabas I. Z historii stosowania konopi w Polsce. Kwartalnik Historii Nauki i Techniki. 1990; 35(2/3): 329–336.
  5. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006; 147 Suppl 1: S163–S171.
  6. Stasiłowicz A, Tomala A, Podolak I, et al. L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment. Int J Mol Sci. 2021; 22(2).
  7. Wężyk K, Słowik A, Bosak M. Predictors of remission in patients with epilepsy. Neurol Neurochir Pol. 2020; 54(5): 434–439.
  8. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51(6): 1069–1077.
  9. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014; 55(6): 783–786.
  10. Brodie MJ, Ben-Menachem E. Cannabinoids for epilepsy: What do we know and where do we go? Epilepsia. 2018; 59(2): 291–296.
  11. Benson MJ, Anderson LL, Low IK, et al. Evaluation of the Possible Anticonvulsant Effect of Δ-Tetrahydrocannabinolic Acid in Murine Seizure Models. Cannabis Cannabinoid Res. 2022; 7(1): 46–57.
  12. Patra PH, Barker-Haliski M, White HS, et al. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. 2019; 60(2): 303–314.
  13. Crocq MA. History of cannabis and the endocannabinoid system
. Dialogues Clin Neurosci. 2020; 22(3): 223–228.
  14. https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-care. (3.01.2022).
  15. Boleti AP, Frihling BE, E Silva PS, et al. Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy. Neurosci Biobehav Rev. 2022; 132: 1214–1228.
  16. Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020; 22(S1): 10–15.
  17. Sharir H, Abood ME. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther. 2010; 126(3): 301–313.
  18. Rosenberg E, Bazelot M, Chamberland S, et al. Cannabidiol(CBD) exerts anti-epileptic actions by targeting the LPI-GPR55signaling system potentiated by seizures. Abstr. 3.052. American Epilepsy Society. ; 2018.
  19. Gray RA, Stott CG, Jones NA, et al. Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent. Cannabis Cannabinoid Res. 2020; 5(2): 145–149.
  20. Ożarowski M, Karpiński TM, Zielińska A, et al. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. Int J Mol Sci. 2021; 22(9).
  21. Juknat A, Gao F, Coppola G, et al. miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia-Effect of cannabinoids. PLoS One. 2019; 14(2): e0212039.
  22. Liou GI, Auchampach JA, Hillard CJ, et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest Ophthalmol Vis Sci. 2008; 49(12): 5526–5531.
  23. Weltha L, Reemmer J, Boison D. The role of adenosine in epilepsy. Brain Res Bull. 2019; 151: 46–54.
  24. Mijangos-Moreno S, Poot-Aké A, Arankowsky-Sandoval G, et al. Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats. Neurosci Res. 2014; 84: 60–63.
  25. Devinsky O, Cross JH, Laux L, et al. Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017; 376(21): 2011–2020.
  26. Miller I, Scheffer IE, Gunning B, et al. GWPCARE2 Study Group. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020; 77(5): 613–621.
  27. Devinsky O, Patel AD, Cross JH, et al. GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018; 378(20): 1888–1897.
  28. Thiele EA, Marsh ED, French JA, et al. GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391(10125): 1085–1096.
  29. Patel AD, Mazurkiewicz-Bełdzińska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021; 62(9): 2228–2239.
  30. Thiele EA, Bebin EM, Bhathal H, et al. GWPCARE6 Study Group. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021; 78(3): 285–292.
  31. Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018; 86: 131–137.
  32. Patel S, Grinspoon R, Fleming B, et al. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy. Epilepsia. 2021; 62(7): 1594–1603.
  33. Park YD, Linder DF, Pope J, et al. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program. Epilepsy Behav. 2020; 112: 107474.
  34. Gaston TE, Ampah SB, Martina Bebin E, et al. UAB CBD Program. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy Behav. 2021; 117: 107862.
  35. Klotz KA, Grob D, Schönberger J, et al. Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study. CNS Drugs. 2021; 35(11): 1207–1215.
  36. Gaston TE, Martin RC, Szaflarski JP. Cannabidiol (CBD) and cognition in epilepsy. Epilepsy Behav. 2021 [Epub ahead of print]; 124: 108316.
  37. Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014; 5(11): 1131–1141.
  38. Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019; 8(7).
  39. Abu-Sawwa R, Scutt B, Park Y. Emerging Use of Epidiolex (Cannabidiol) in Epilepsy. J Pediatr Pharmacol Ther. 2020; 25(6): 485–499.
  40. Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015; 56(8): 1246–1251.
  41. Gaston TE, Bebin EM, Cutter GR, et al. Szaflarki JP for the UAB CBD programme. In-teractions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017; 70: 313–8.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl